Andrew Rem

George Melas

George Melas-Kyriazi

Jane Lindemann

Jane Lindenman

Russell Tolander

- ImmuCell Corporation reported strong financial results for the **first half of 2025**, with approximately **14% year-over-year revenue growth**, **$1.9 million in net income**, and **$3.7 million in adjusted EBITDA**.  **[811641_2162799_4]**  This performance benefited from the restocking of the distribution channel after a period of backlog.  **[811641_2162799_4]** 
- The company has resolved significant manufacturing contamination issues that affected operations from late 2022 through early 2024, and has been running cleanly since **April 2024**.  **[811641_2162799_2]** **[811641_2162799_3]**  Current production capacity supports **$30 million or more in revenue**, with plans to invest approximately **$3 million** to expand capacity to support **$40 million or more in revenue** within an estimated **18 months**.  **[811641_2162799_3]** 
- ImmuCell's second key product, Re-Tain, for mastitis, is in the late stages of FDA approval, with four of five technical sections complete.  **[811641_2162799_4]**  The final manufacturing section is pending resolution of a contract manufacturer's inspection with the FDA.  **[811641_2162799_4]** 
- **Michael Brigham**, CEO, will be stepping down around **year-end 2025** as part of a succession plan, with a search for his successor underway and progressing well.  **[811641_2162799_5]**  He will remain involved through the board.  **[811641_2162799_5]**

IMMUCELL CORP /DE/ (ICCC)